Tanner Pharma Group Initiates Named Patient Program for XIAFLEX®

Tanner Pharma Group Initiates Named Patient Program for XIAFLEX®

March 2, 2020 08:00 AM Eastern Daylight Time

CHARLOTTE, NC –Tanner Pharma Group, Inc. today announced they have partnered with Endo Pharmaceuticals, Inc. to initiate a multi-year Named Patient Program for XIAFLEX® (collagenase clostridium histolyticum), an important nonsurgical treatment option for patients with Dupuytren’s contracture and Peyronie’s disease.
XIAPEX®, also owned by Endo, was previously marketed by Swedish Orphan Biovitrum AB (Sobi) in the EU and other European countries until the withdrawal of its EU Marketing Authorization on March 1, 2020. The decision to withdraw was not based on safety or efficacy concerns. The agreement names Tanner Pharma Group as the exclusive provider of the U.S. product XIAFLEX in markets previously served by Sobi, to address the unmet need for collagenase injection therapy.
Banks Bourne, Chairman and Founder of Tanner Pharma Group, commented, “We are pleased to support physicians who were previously using XIAPEX by providing an ethical and compliant route to an alternative product. Our unique delivery model will minimize the disruption caused by this withdrawal and will ensure that collagenase injection therapy remains an option for European healthcare professionals and patients.”
Healthcare professionals can obtain details about the XIAFLEX Named Patient Program by contacting Tanner at:

                                                                                    Telephone +44 (0) 2039 408111
                                                                                             Email xiaflex@tannerpharma.com

About XIAFLEX:

Initially approved by the US FDA in 2010, XIAFLEX is a combination of bacterial collagenases indicated for the treatment of Dupuytren’s contracture in adult patients with a palpable cord and for the treatment of adult men with Peyronie’s disease with a palpable plaque and curvature deformity of at least 30 degrees at the start of therapy. XIAFLEX represents an important nonsurgical treatment option for these patients, which works through enzymatic disruption of collagen cords and plaques.

About Endo:

Endo Pharmaceuticals Inc., an operating subsidiary of Endo International plc (NASDAQ: ENDP), is a highly focused generics and specialty branded pharmaceuticals company delivering quality medicines to patients in need through excellence in development, manufacturing and commercialization. Endo has global headquarters in Dublin, Ireland, and U.S. headquarters in Malvern, PA. Learn more at www.endo.com

Tanner Pharma Group uses cookies on its website. By continuing to access this website you are agreeing to Tanner Pharma Group’s Data Privacy Policy. For more information, click here.